Trials / Unknown
UnknownNCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Kartos Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KRT-232 | KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth |
| DRUG | acalabrutinib | acalabrutinib is a BTK inhibitor anticancer drug taken by mouth |
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2022-10-01
- Completion
- 2024-03-01
- First posted
- 2020-08-06
- Last updated
- 2022-08-04
Locations
45 sites across 11 countries: United States, Australia, Belgium, Czechia, France, Italy, Poland, Portugal, South Korea, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04502394. Inclusion in this directory is not an endorsement.